
BCAX Stock Forecast & Price Target
BCAX Analyst Ratings
Bulls say
Bicara Therapeutics Inc.'s ficerafusp alfa, a bifunctional antibody, demonstrates significantly higher objective response rates (ORR) compared to established treatments, achieving a meaningful superiority to Keytruda's performance in similar patient populations. The combination of ficerafusp alfa with Keytruda showcases promising survival metrics, with a median progression-free survival (mPFS) of 9.9 months and median overall survival (mOS) of 21.3 months, suggesting enhanced therapeutic efficacy. These favorable clinical outcomes position Bicara Therapeutics favorably within the highly competitive oncology market, indicating potential for substantial growth and value for investors.
Bears say
Bicara Therapeutics reported a net loss of $0.50 per share for the second quarter of 2025, consistent with prior estimates, highlighting ongoing financial challenges. The company faces multiple risks that could adversely affect its operations, including the potential for negative clinical results with its lead candidate ficerafusp alfa, delays in progressing this therapy into crucial registrational trials, and difficulties in obtaining necessary regulatory approvals. Additionally, the competitive landscape for bispecific therapies further exacerbates concerns, coupled with the potential for long-term dilution of shareholder value.
This aggregate rating is based on analysts' research of Bicara Therapeutics Inc and is not a guaranteed prediction by Public.com or investment advice.
BCAX Analyst Forecast & Price Prediction
Start investing in BCAX
Order type
Buy in
Order amount
Est. shares
0 shares